Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature

  • Yassir Sbitti1Email author,
  • Hafsa Chahdi2,
  • Khaoula Slimani1,
  • Adil Debbagh1,
  • Anouar Mokhlis1,
  • Abderrahmane Albouzidi2,
  • Fahd Bennani1,
  • Hassan Errihani3 and
  • Mohamed Ichou1
Journal of Medical Case Reports201711:182

https://doi.org/10.1186/s13256-017-1348-6

Received: 28 December 2016

Accepted: 5 June 2017

Published: 28 July 2017

Abstract

Background

Pemetrexed maintenance therapy holds tremendous potential in improving the survival of patients with advanced pulmonary adenocarcinoma. Major side effects include myelosuppression and cutaneous reactions. However, little data are available on pemetrexed nephrotoxicity. Our case describes clinically relevant renal events leading to treatment discontinuation in routine practice.

Case presentation

We report a case of a 69-year-old Moroccan man treated for metastatic non-small cell lung cancer. He was not on any other medications and he did not receive any nephrotoxic agents. He was exposed to intravenously administered contrast from thoracoabdominal computed tomography in the week of his last pemetrexed treatment. He developed kidney disease related to pemetrexed. He was submitted to renal biopsy, which showed acute tubular damage and interstitial fibrosis. His kidney function remained impaired, but stable, after discontinuation of pemetrexed therapy. He died 5 months later.

Conclusions

Medical oncologists should be aware of renal adverse events for patients with advanced non-small cell lung cancer eligible for pemetrexed maintenance therapy. Suggestions for mitigating the risk for renal toxicities (dehydration, non-steroidal anti-inflammatory drugs and zoledronic acid, radiocontrast agents) during pemetrexed maintenance should be followed to enable early detection and management of this adverse event.

Keywords

Pemetrexed Renal damage Non-small cell lung carcinoma

Background

Maintenance therapy has emerged as a novel therapy for patients with non-progressive advanced non-squamous cell lung cancer after induction. The value of maintenance therapy is now statistically established [1, 2]. However, not all patients need maintenance therapy and the risk of acute and cumulative toxicities may be increased. The main adverse effects of pemetrexed include myelosuppression, which may be prevented by folic acid and vitamin B12 supplementation. The most common non-hematologic side effect is elevation of hepatic enzyme levels. Other toxicities include rash, mucositis, nausea, and vomiting [25]. Pemetrexed nephrotoxicity is well known; however, its frequency is considered to be low [5]. The mechanism responsible for renal damage remains unknown. Recently, several cases of pemetrexed-induced tubular injury were reported in the international literature [610] including interstitial nephritis and fibrosis, as well as diabetes insipidus. Only a few patients were submitted to renal biopsy. We report a case of renal insufficiency as a leading cause of maintenance pemetrexed discontinuation for toxicity to advanced non-small cell lung cancer in routine practice.

Case presentation

A 69-year-old Moroccan man presented to our medical oncology department in January 2015. He was an ex-tobacco smoker (45 packs/year). His past medical history was unremarkable and he took no medications. His performance status was Eastern Cooperative Oncology Group (ECOG) 1. He was diagnosed as having primary advanced lung adenocarcinoma. Oncogenic driver mutations such as epidermal growth factor receptor or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene were not performed. He was treated with first-line chemotherapy, including 3-hour paclitaxel infusions at dose (200 mg/m2, days 1) and carboplatin (area under the curve, 5), every 3 weeks for four cycles. After four consecutive 21-day cycles of chemotherapy, the disease had partially responded. He developed grade II peripheral neuropathy induced by paclitaxel according to Common Terminology Criteria for Adverse Events (CTCAE). He was then started on pemetrexed switch maintenance at dose of 500 mg/m2 (900 mg) every 3 weeks. He was premedicated with steroids and was receiving vitamin B12 injections. His serum creatinine (SCr) prior to pemetrexed administration was 0.8 mg/dl; Modification of Diet in Renal Disease (MDRD) estimated glomerular filtration rate (GFR) 85 ml/minute per 1.73 m2. After third cycle of pemetrexed infusion, his creatinine clearance (Cr Cl) started to drop, up to 25 ml/minute per 1.73 m2. Pemetrexed was stopped. Our patient was referred to a nephrologist. On admission, his blood pressure was 140/80 mmHg and a physical examination was normal. Sporadic consumption of non-steroidal anti-inflammatory drugs (NSAIDs) was reported. He was exposed to intravenously administered contrast from thoracoabdominal computed tomography (CT) in the week of his last pemetrexed treatment. Serum electrolyte levels and renal ultrasound were both normal. A 24-hour urine collection revealed a 0.7 g proteinuria without hematuria, glycosuria, leukocyturia, or proximal tubular dysfunction. Critical measures including maintaining adequate intravascular volume and mean arterial pressure, discontinuing pemetrexed drug, and eliminating exposure to nephrotoxins were performed. SCr level control was 2.2 mg/dl (MDRD estimated GFR 25 ml/minute per 1.73 m2). A kidney biopsy was performed. Renal biopsy specimen showed acute tubular necrosis with interstitial inflammatory infiltrate of mononuclear cells and interstitial fibrosis occupying 40% of renal cortex (Fig. 1). His SCr level was stable 4 months after the last dose of pemetrexed. He died 5 months later.
Fig. 1

Kidney biopsy showed interstitial infiltration from many inflammatory cells, mainly mononuclear cells. (Hematoxylin and eosin stain, original magnification × 400. Masson’s trichrome)

Discussion

In patients with advanced lung adenocarcinoma, the results of phase III trials show that pemetrexed maintenance therapy allows longer survival [1, 2]. Given pemetrexed safety and simple intravenous administration every 3 weeks, this strategy seems to be of important clinical value. However, not all patients need or benefit from maintenance therapy. Events associated with decreased renal function were reported [35, 11]. In phase III trials, all grades of renal failure and grade 4 requiring dialysis were reported in 2.4 and 0.6% of patients, respectively [5]. Our case report describes renal insufficiency as a leading cause of maintenance pemetrexed discontinuation for toxicity to advanced non-small cell lung cancer in routine practice. Cr Cl decreased from 85 to 25 ml/minute per 1.73 m2 following the third pemetrexed infusion. This observed nephrotoxicity seems to be related to the mechanism of action of pemetrexed and its pharmacokinetics. Pemetrexed was eliminated as unchanged drug primarily from the kidney, by both tubular secretion and glomerular filtration with the former being the predominant mechanism for patients with normal renal function [12, 13]. Only a few patients were submitted to renal biopsy. Our patient experienced acute tubular necrosis and interstitial fibrosis following sequential treatment with pemetrexed. Our data are in agreement with other reports where renal injury has been reported after three, four, or six cycles of pemetrexed [610, 14, 15]. After discontinuation of pemetrexed, our patient’s renal function stabilized, but did not return to pre-treatment baseline. Although many acute kidney injury (AKI) risk factors were present (dehydration, NSAIDs, radiocontrast agents), none of them seemed to be responsible for kidney injury. The lapse of time between the administration of radiocontrast agents and AKI development excludes radiocontrast agent-induced nephropathy. Interstitial fibrosis was attributed to pemetrexed. However, we cannot exclude the contribution of these factors. Thus, pemetrexed must be considered an important cause of renal failure in patients with cancer. However, it is difficult to identify patients at higher risk of discontinuation based only on changes in laboratory values. Oncologists have to be vigilant in assessing their patient’s renal function for treatment.

Conclusions

In conclusion, suggestions for mitigating the risk for renal toxicities during pemetrexed maintenance should be followed. Cr Cl must be measured before each cycle of pemetrexed administration. CT scans with contrast should be performed a few days to 1 week after pemetrexed administration. Patients must be appropriately hydrated during treatment. Concomitant medications should be reviewed with the patient and, when possible, medications that could potentially be nephrotoxic should be eliminated. A decision to use maintenance chemotherapy requires a discussion between patient and physician that adequately assesses the benefits of prolonged therapy and the impact in terms of toxicity and quality of life.

Abbreviations

AKI: 

Acute kidney injury

Cr Cl: 

Creatinine clearance

CT: 

Computed tomography

CTCAE: 

Common Terminology Criteria for Adverse Events

ECOG: 

Eastern Cooperative Oncology Group

GFR: 

Glomerular filtration rate

MDRD: 

Modification of Diet in Renal Disease

NSAIDs: 

Non-steroidal anti-inflammatory drugs

SCr: 

Serum creatinine

Declarations

Acknowledgements

We are very grateful to the wife of our patient for providing his informed consent for publication of this case report and we are indebted to our families for their continuous support and encouragement.

Funding

There is no source of funding to declare.

Availability of data and materials

All data generated or analyzed during this study are included in this published article. The authors presented all the necessary information about their case report in the manuscript. Regarding the literature review, all used literature was referenced appropriately in the References section.

Authors’ contributions

YS designed and wrote the paper. HC and AA provided pathological diagnosis. YS, AD, KS, AM, MI, and FB participated in medical treatment. MI and HE designed the paper. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written informed consent was obtained from the patient’s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medical Oncology, University Military Hospital
(2)
Department of Pathology, University Military Hospital
(3)
Department of Medical Oncology, National Institute of Oncology

References

  1. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double blind, phase 3 study. Lancet. 2009;374:1432.View ArticlePubMedGoogle Scholar
  2. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895.View ArticlePubMedGoogle Scholar
  3. Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004;5 suppl 2:S51–5.View ArticlePubMedGoogle Scholar
  4. Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy. 2006;26:641–54.View ArticlePubMedGoogle Scholar
  5. Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function [see comment]. J Clin Oncol. 2006;24:552–62.View ArticlePubMedGoogle Scholar
  6. Porta JM, Vicente de Vera Floristán C, Inglán PB, Jericó JF. Acute renal failure associated with pemetrexed. Nefrologia. 2009;29:610–1.PubMedGoogle Scholar
  7. Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol. 2009;2:53–6.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Stavroulopoulos A, Nakopoulou L, Xydakis AM, Aresti V, Nikolakopoulou A, Klouvas G. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail. 2010;32:1000–4.View ArticlePubMedGoogle Scholar
  9. GlezermanI G, Pietanza MC, Miller V, Seshan SV. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis. 2011;58:817–20.View ArticleGoogle Scholar
  10. Chauvet S, Courbebaisse M, Ronco P, Plaisier E. Pemetrexed-induced acute kidney injury leading to chronic kidney disease. Clin Nephrol. 2014;82(12):402–26.View ArticlePubMedGoogle Scholar
  11. Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M, Forouzesh B, et al. Pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res. 2007;13:2675–83.View ArticlePubMedGoogle Scholar
  12. Gridelli C, de Marinis F, Thomas M, et al. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. J Thorac Oncol. 2014;9:991.View ArticlePubMedGoogle Scholar
  13. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004;9(5):482–8.View ArticlePubMedGoogle Scholar
  14. U.S Food and drug Administration. Center of Drug Evaluation and Research: Alimta. 2004. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021677s000_alimtatoc.cfm.
  15. Vootukuru V, Liew YP, Nally JV. Pemetrexed-Induced Acute Renal Failure, Nephrogenic Diabetes Insipidus, and Renal Tubular Acidosis in a Patient with Non-Small Cell Lung Cancer. Med Oncol. 2006;23(3):419–22.Google Scholar

Copyright

© The Author(s). 2017

Advertisement